At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Cemiplimab +1 moredrug
Likely dose
Cemiplimab 350 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Nov 26, 2019·Updated Feb 23, 2024
In Brief
A Phase 2 clinical trial evaluating Cemiplimab and Plerixafor for Metastatic Pancreatic Cancer. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and clinical activity of plerixafor in combination with cemiplimab in patients with metastatic pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Cancer
CountriesUnited States
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartNov 2020
Primary CompletionMar 2023
Study CompletionMay 2023
TodayJul 2026
First PostedNov 26, 2019
Enrollment StartNov 16, 2020
Primary CompletionMar 29, 2023
Study CompletionMay 19, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.6 years ago
Interventions
Cemiplimabdrug
Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years.
Plerixafordrug
Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years.